Laekna, Inc. (2105.HK) announced that on November 12, 2025, the company and Qilu Pharmaceutical Company Limited (Qilu Pharma) entered into an exclusive licensing agreement. Qilu Pharma gains rights to research, develop, and commercialize LAE002 (afuresertib) in Mainland China, Hong Kong, Macau, and Taiwan.
Under the agreement, Laekna, Inc. remains responsible for completing its ongoing Phase III clinical trial (AFFIRM-205) for HR+/HER2- breast cancer. The company is entitled to receive payments of up to RMB2,045 million in total, including up to RMB530 million upon the approval of a new drug application for the first indication. Tiered royalty rates from the low teens to the low twenties on future net sales of LAE002 in the licensed territories are also included.
According to the company, the collaboration is intended to accelerate the regulatory approval and commercialization of afuresertib while strengthening its financial position. The Phase III study is currently on track, with the goal of completing subject enrollment in the fourth quarter of 2025 and submitting a new drug application in 2026.
Laekna, Inc. highlights that afuresertib is a potent AKT inhibitor in late-stage development for breast and prostate cancers globally. Qilu Pharma is described as a leading vertically integrated pharmaceutical company in China, specializing in developing, manufacturing, and distributing finished dosage forms and active pharmaceutical ingredients.
The announcement states that LAE002 may ultimately not be successfully developed or commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the securities of Laekna, Inc.
Comments